Alderbio Holdings LLC

Vitaeris Inc.

Alder Biopharmaceuticals, Inc.

Anne Elisabeth Carvalho Jensen

John A Latham

Leon F Garcia-Martinez

Brian Robert Kovacevich

Jeffrey T L Smith

Ethan Wayne Ojala

Benjamin H Dutzar

Katie Olson Anderson

Katie Olson

Ben Dutzar

Mark Litton

Randall Schatzman

John Latham

Jeffrey Tl Smith

Brian Kovacevich

Jeffrey TI Smith

Kate Olson

Leon Garcia - Martinez

Leon Garcia

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing.

Antibodies to IL-6 and use thereof

Methods of treating individuals with autoimmune conditions characterized by elevated IL-6 levels comprising the administration of anti-IL-6 antibodies or antibody fragments are provided.

Methods of treating autoimmunity using specific anti-IL-6 antibodies

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. Additional preferred embodiments of the subject invention relate to therapeutic compositions and methods treating or preventing rheumatoid arthritis, especially subcutaneous and intravenous formulations and dosage regimens using IL-6 antagonists according to the invention, as well as methods for preventing or treating GVHD or leukemia relapse in subjects receiving transplanted cells, tissue or organs, use thereof in the treatment or prevention of mucositis, and use thereof to potentiate the cytotoxic, apoptotic, and anti-metastatic or anti-invasive effects of chemotherapeutics and radiation on cancers, especially cancers that have developed a resistance to radiation or chemotherapy, such as an EGFR inhibitor.

Method of treating allergic asthma with antibodies to IL-6

Isolated host cells expressing anti-IL-6 antibodies

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.

Methods of aiding in the diagnosis of diseases using anti-IL-6 antibodies

The present invention is directed to antibodies and fragments thereof having binding specificity for TNF-&#x3b1;. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, Vand CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-TNF-&#x3b1; antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-TNF-&#x3b1; antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-TNF-&#x3b1; antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with TNF-&#x3b1;.

Antibodies to TNF &#x3b1; and use thereof

Subcutaneously administrable composition containing anti-IL-6 antibody

Methods of treating anemia in chronic diseases where IL-6 is elevated using IL-6 antagonist antibodies are provided.

Treating anemia in chronic IL-6 associated diseases using anti-IL-6 antibodies

Nucleic acids encoding anti-IL-6 antibodies of defined epitopic specificity

The invention relates to anti-human interleukin 6 antibodies and antibody fragments, nucleic acids and vectors which encode for these antibodies and antibody fragments the use thereof in therapy and diagnosis.

Expression vectors containing isolated nucleic acids encoding anti-human IL-6 antibody

Growing community of inventors

Edmonds, WA, United States of America

Anne Elisabeth Carvalho Jensen